Health Care·Biotechnology·$2.2B
GRAIL Inc. is a biotechnology company focused on early cancer detection through innovative blood tests....
EPS
Earnings per share is crucial for understanding the company's profitability and performance relative to expectations.
Revenue
Revenue figures provide insight into the company's sales performance and market demand for its products.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
5Q
EPS Beat Rate
83%
Avg EPS Surprise
+20.96%
Avg Stock Reaction
+2.05%
In Q4-2025, GRAIL reported an EPS of $-2.44, which was better than analyst expectations of $-3.33, marking a positive surprise. However, revenue details were not disclosed.
Management Promises & Guidance
Analysts expect GRAIL to report a narrower loss and modest revenue growth this quarter. The market will be closely watching how the company continues to innovate in cancer detection.
Bull Case
If GRAIL can demonstrate significant advancements in its technology and report better-than-expected revenue, it could boost investor confidence and drive stock prices higher.
Bear Case
Conversely, if the company fails to meet revenue expectations or shows signs of stagnation in its product development, it may lead to a decline in stock value.
EPS
$-1.96Earnings per share is crucial for understanding the company's profitability and performance relative to expectations.
Revenue
$39MRevenue figures provide insight into the company's sales performance and market demand for its products.
The print will turn on these two things.
Q1
Will GRAIL's reported revenue meet or exceed the $39M consensus?
Meeting or exceeding revenue expectations will be critical in demonstrating market demand for its cancer detection products.
Q2
How does GRAIL plan to address its ongoing losses, particularly the expected EPS of $-1.96?
Investors will be keen to understand the company's strategy for improving profitability and reducing losses moving forward.
Why consensus could be wrong
The consensus may underestimate GRAIL's potential for revenue growth due to recent advancements in its technology that have not been fully accounted for.
Supporting Evidence
GRAIL has consistently beaten EPS estimates in the past, indicating potential for positive surprises.
The options market is pricing a significant move, suggesting that investors are anticipating a notable change in sentiment.
Recent advancements in cancer detection technology may lead to increased adoption and sales that analysts are not fully factoring in.
Key Risk
If GRAIL reports revenue significantly above $39M, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
The market is evaluating GRAIL's ability to innovate and grow in a competitive biotechnology landscape, making these metrics critical.
Bull Confirmed If
Reporting revenue above $39M and an EPS loss narrower than $-1.96 would confirm the bull case.
Bear Confirmed If
An EPS loss greater than $-1.96 and revenue below $37M would support the bear case.
Implied Move
±15.05%
Historical Avg
±5.8%
The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings report.
Options are pricing ±15.1% while GRAL has averaged ±5.8% over the last 6 prints — setup is pricing rich.
Likely market behavior by outcome — not investment advice.
Beat & Raise
If GRAIL beats expectations, history suggests the stock could rise by around 2.74%, confirming positive market sentiment.
In-Line / Cautious
A report in line with expectations may lead to a muted reaction, as investors await further guidance.
Miss
If GRAIL misses on both EPS and revenue, history suggests a potential decline of around 5.82%, reflecting disappointment in performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PARAMOUNT SKYDANCE C Class B
May 4, 2026